Company signs research agreement with Pfizer to study adipose tissue.
JUPITER, Fla., May 22, 2014 -- BioRestorative Therapies, Inc. (BRTX) has entered into a two-year collaborative research agreement with Pfizer Inc. to study human brown adipose tissue and cell lines.
BRT and Pfizer will jointly conduct a study titled "Development and Validation of a Human Brown Adipose Cell Model," which will seek to further characterize the identity and metabolic function of these cell lines.
BRT has accumulated a large collection of human brown adipose tissue samples, preadipocyte cell lines and immortalized cell lines for use in potentially developing a cell therapy product. The results of the research may be used by both companies.
Brown fat is a population of adipose (fat) tissue found in the human body and plays a key role in the evolutionarily conserved mechanisms underlying energy homeostasis in mammals.
In June 2011, BRT launched the initial research phase of what it believes will develop into a technology that involves the use of brown fat in a cell-based therapeutic program referred to as the ThermoStem Program. The program will focus on treatments for type 2 diabetes and obesity, as well as for hypertension, other metabolic disorders and cardiac deficiencies, and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Strategic Alliances|
|Publication:||Stem Cell Lab World|
|Date:||Jun 2, 2014|
|Previous Article:||Clinical trial in age-related macular degeneration advances to final cohort.|
|Next Article:||Companies partner to study novel drug targets in cardiovascular disease.|